May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Intraocular Gene Delivery of Soluble VEGF Receptors
P. Pechan; M. Lukason; H.L. Rubin; A. Scaria; S. Wadsworth
Author Affiliations & Notes
  • P. Pechan
    Gene Therapy, Genzyme Corporation, Framingham, MA
  • M. Lukason
    Gene Therapy, Genzyme Corporation, Framingham, MA
  • H.L. Rubin
    Gene Therapy, Genzyme Corporation, Framingham, MA
  • A. Scaria
    Gene Therapy, Genzyme Corporation, Framingham, MA
  • S. Wadsworth
    Gene Therapy, Genzyme Corporation, Framingham, MA
  • Footnotes
    Commercial Relationships  P. Pechan, Genzyme Corp. E; M. Lukason, Genzyme Corp. E; H.L. Rubin, Genzyme Corp. E; A. Scaria, Genzyme Corp. E; S. Wadsworth, Genzyme Corp. E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3712. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Intraocular Gene Delivery of Soluble VEGF Receptors
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      P. Pechan, M. Lukason, H.L. Rubin, A. Scaria, S. Wadsworth; Intraocular Gene Delivery of Soluble VEGF Receptors . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3712.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose:Many studies have shown that vascular endothelial growth factor (VEGF) plays a critical role in development of choroidal and retinal neovascularization. Therefore, antagonizing VEGF is a potentially useful strategy for treating such disorders. In current study we are evaluating the relative efficacy of various truncated and full–length versions of soluble VEGF receptors, VEGF–R1 (sFlt–1) and VEGF–R2 (sKDR), toward inhibiting neovascularization. Methods:Biological potency of various versions was ranked in vitro using Human Vascular Endothelial Cell (HUVEC) proliferation and migration assays. Candidate genes were then inserted into adenovirus type 2 (Ad2) or adeno–associated virus type 2 (AAV2) gene transfer vectors. The efficacy of Ad2 and AAV2 vectors is being evaluated in vivo by intravitreal injection in the mouse retinopathy of prematurity (ROP) model. The extent of retinal neovascularization is measured both by fluorescein angiography and histology. Results:Several versions of sFlt–1 were potent inhibitors of VEGF–dependent HUVEC proliferation and migration assays. Our preliminary results show that intravitreal delivery of 5x108 particles of Ad2/sFlt–1 significantly decreased retinal neovascularization in the ROP model. Evaluation of safety and efficacy following single and multiple vector administrations is underway. Conclusions:As reported by other investigators, intravitreal injection is an efficient method of gene transfer into the eye. Virus vector mediated delivery of sFlt–1 appears to be a promising tool for the inhibition of retinal neovascularization.

Keywords: gene transfer/gene therapy • retinal neovascularization • growth factors/growth factor receptors 
© 2004, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept